Annual antineoplastic medicine sales in Russia reached three billion Russian rubles in 2020. The revenue marked a continuous growth over the observed period, increasing by 700 million compared to the previous year.
Sales revenue of antineoplastic medications in Russia from 2018 to 2020 (in billion Russian rubles)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$59 USD $39 USD / Month *
in the first 12 months
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Statistics on Pharmaceutical industry in Russia
Overview
8
- Premium Statistic Pharmaceutical sales revenue in CIS 2021, by country
- Premium Statistic Pharmaceutical market size in Russia 2012-2024
- Premium Statistic Pharmaceutical market size in Russia 2017-2024, by segment
- Basic Statistic Commercial pharma market value in Russia monthly 2021-2022
- Premium Statistic Pharmaceutical sales volume share in Russia 2022, by price category
- Premium Statistic Pharmaceutical production value in Russia 2015-2022
- Premium Statistic Inflation on pharmaceuticals in Russia 2008-2021
- Premium Statistic Medicines and medical materials investment in Russia 2015-2021
Segments
7
- Premium Statistic Medication sales volume share in Russia 2019-2021, by type
- Premium Statistic Generic and original medication sales volume share in Russia 2019-2021
- Premium Statistic Russia: revenue of cold and cough remedies 2016-2027
- Basic Statistic Spending on medication against COVID-19 Russia 2021, by type
- Premium Statistic Russia: revenue of skin treatment products 2016-2027
- Premium Statistic Biologically active additives market value in Russia 2016-2022
- Premium Statistic Pharmaceutical cosmetics sales value in Russia 2017-2021
Companies and brands
7
- Premium Statistic Leading pharmaceutical producers in Russia 2021, by revenue
- Premium Statistic Leading Russian pharmaceutical companies 2020, by indicator
- Premium Statistic Leading pharma distributors in Russia 2022, by revenue
- Premium Statistic Most popular medications in Russia 2021, by sales value
- Premium Statistic Highest-earning producers of biologically active additives in Russia 2021
- Premium Statistic Highest-earning brands of biologically active additives in Russia 2021
- Premium Statistic COVID-19 medicine share in pharma revenue in Russia 2021, by company
Pharmacies
5
- Premium Statistic Pharmacy count in Russia 2015-Q4 2022
- Premium Statistic Pharmacy count in Russia Q1 2021, by region
- Premium Statistic Average monthly pharmacy revenue in Russia Q1 2021, by region
- Premium Statistic Leading conventional pharmacies in Russia 2022, by market share
- Premium Statistic Omnichannel performance ranking of pharmacies in Russia 2021
Online retail
4
Trade
7
- Premium Statistic Pharmaceutical export value in Russia 2015-2021
- Premium Statistic Pharma exports from Russia 2021, by country
- Premium Statistic Vaccine export value in Russia 2019-2021
- Premium Statistic Number of vaccine doses exported from Russia 2019-2021
- Basic Statistic Vaccine export value from Russia 2021, by country
- Premium Statistic Pharmaceutical import value in Russia 2015-2022, by type
- Premium Statistic Pharma imports in Russia 2021, by country
Further related statistics
17
- Unsuccessful developing brain cancer drugs in the U.S. 1998-2014
- Unsuccessful developing lung cancer drugs in the U.S. 1998-2014
- Geographic distribution of oncology clinical trials 2008-2013, by cancer
- Age distribution of oncology clinical trials globally 2008-2013, by cancer
- Average prices of Gleevec - selected countries 2013
- Total R&D costs of select cancer drugs 2017
- Unsuccessful attempts and new drugs for cancer types 1998-2014
- Revenue since approval for select cancer drugs 2017
- Revenue as a part of R&D spending for select cancer drugs 2017
- Worldwide revenue of cancer drugs
- Top cancer drugs paid by Medicare Part B by sales price per dosage 2014
- Proportion of cancer drugs on the world pharmaceutical market
- Public expenditure on innovative drugs in Italy 2017-2020
- Italy: oncologists' opinion about scarcity of resources to treat cancer patients 2018
- USA: Active ingredients in anti-cancer drugs 2004-2013
- Public expenditure on the most prescribed drugs in Italy 2020, by category
- Expensive cancer drugs by annual Medicare payments in the U.S. 2014
Further Content: You might find this interesting as well
Statistics
- Unsuccessful developing brain cancer drugs in the U.S. 1998-2014
- Unsuccessful developing lung cancer drugs in the U.S. 1998-2014
- Geographic distribution of oncology clinical trials 2008-2013, by cancer
- Age distribution of oncology clinical trials globally 2008-2013, by cancer
- Average prices of Gleevec - selected countries 2013
- Total R&D costs of select cancer drugs 2017
- Unsuccessful attempts and new drugs for cancer types 1998-2014
- Revenue since approval for select cancer drugs 2017
- Revenue as a part of R&D spending for select cancer drugs 2017
- Worldwide revenue of cancer drugs
- Top cancer drugs paid by Medicare Part B by sales price per dosage 2014
- Proportion of cancer drugs on the world pharmaceutical market
- Public expenditure on innovative drugs in Italy 2017-2020
- Italy: oncologists' opinion about scarcity of resources to treat cancer patients 2018
- USA: Active ingredients in anti-cancer drugs 2004-2013
- Public expenditure on the most prescribed drugs in Italy 2020, by category
- Expensive cancer drugs by annual Medicare payments in the U.S. 2014
pharmvestnik.ru. (April 21, 2021). Sales revenue of antineoplastic medications in Russia from 2018 to 2020 (in billion Russian rubles) [Graph]. In Statista. Retrieved March 29, 2023, from https://www.statista.com/statistics/1236204/antineoplastic-medicine-sales-revenue-russia/
pharmvestnik.ru. "Sales revenue of antineoplastic medications in Russia from 2018 to 2020 (in billion Russian rubles)." Chart. April 21, 2021. Statista. Accessed March 29, 2023. https://www.statista.com/statistics/1236204/antineoplastic-medicine-sales-revenue-russia/
pharmvestnik.ru. (2021). Sales revenue of antineoplastic medications in Russia from 2018 to 2020 (in billion Russian rubles). Statista. Statista Inc.. Accessed: March 29, 2023. https://www.statista.com/statistics/1236204/antineoplastic-medicine-sales-revenue-russia/
pharmvestnik.ru. "Sales Revenue of Antineoplastic Medications in Russia from 2018 to 2020 (in Billion Russian Rubles)." Statista, Statista Inc., 21 Apr 2021, https://www.statista.com/statistics/1236204/antineoplastic-medicine-sales-revenue-russia/
pharmvestnik.ru, Sales revenue of antineoplastic medications in Russia from 2018 to 2020 (in billion Russian rubles) Statista, https://www.statista.com/statistics/1236204/antineoplastic-medicine-sales-revenue-russia/ (last visited March 29, 2023)
Sales revenue of antineoplastic medications in Russia from 2018 to 2020 (in billion Russian rubles) [Graph], pharmvestnik.ru, April 21, 2021. [Online]. Available: https://www.statista.com/statistics/1236204/antineoplastic-medicine-sales-revenue-russia/